Eckert & Ziegler Reduces Dividend to Finance Future Investments. Earnings Growth Expected for 2024.
March 19, 2024 at 06:48 pm
Share
EQS-Ad-hoc: Eckert & Ziegler SE / Key word(s): Dividend
Eckert & Ziegler Reduces Dividend to Finance Future Investments. Earnings Growth Expected for 2024.
19-March-2024 / 19:46 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Berlin, 19 March 2024 – The Supervisory Board and Executive Board of Eckert & Ziegler (ISIN DE0005659700, TecDAX) today decided to propose to the Annual General Meeting a reduced dividend of € 0.05 per share entitled to a dividend. The liquidity thus remaining in the company will be used to finance new high-return projects in the continuously growing market for radiopharmaceuticals. This includes, in particular, the expansion of global production capacities. The dividend reduction is also intended to ensure greater independence from external financing.
In addition to the reduced dividend, EZAG shareholders are to receive one additional Pentixapharm share for each EZAG share in the course of the planned split-off of Pentixapharm AG.
In the 2023 financial year, the Eckert & Ziegler Group increased sales by 11% to € 246.1 million. Net profit for the year amounted to € 26.3 million corresponding to earnings per share of € 1.26.
For the 2024 financial year, the Executive Board expects sales of just under € 265 million and EBIT from continuing operations before one-off effects of around € 50 million.
The detailed annual financial statements for 2023 will be published on March 22, 2024.
19-March-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com
Language:
English
Company:
Eckert & Ziegler SE
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone:
+49 30 941084-138
Fax:
+49 30 941084-0
Internet:
www.ezag.de
ISIN:
DE0005659700
WKN:
565970
Indices:
SDAX, TecDax,
Listed:
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
Eckert & Ziegler SE is a Germany-based Company, which is a provider of isotope technology for medical, scientific and industrial use with focus on cancer therapy, industrial radiometry and nuclear-medical imaging. The Company operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.